Related Experiment Video

Updated: Jun 16, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

The dark side of the moon: the PI3K/PTEN/AKT pathway in colorectal carcinoma

Nicola Silvestris1, Stefania Tommasi, Daniela Petriella

  • 1Medical and Experimental Oncology Unit, Cancer Institute Giovanni Paolo II, Bari, Italy. n.silvestris@oncologico.bari.it

Oncology
|February 5, 2010
PubMed

Insights

Wild-type KRAS is necessary but not sufficient for anti-EGFR therapy response in colorectal cancer. Researchers are exploring other biomarkers like PIK3CA mutations and PTEN loss to predict treatment resistance.

Area of Science:

  • Oncology
  • Molecular Biology
  • Gastroenterology

Background:

  • Sensitivity to anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs) in colorectal cancer (CRC) requires wild-type KRAS, but this is not always sufficient.
  • Identifying additional predictive markers for anti-EGFR therapy resistance in KRAS wild-type CRC patients remains a significant clinical challenge.

Purpose of the Study:

  • To review and synthesize current knowledge on biomarkers predicting response or resistance to anti-EGFR mAbs in CRC.
  • To discuss the role of PIK3CA mutations and PTEN loss as potential predictors of resistance.
  • To highlight the emerging therapeutic strategies targeting the PI3K/AKT/mTOR pathway.

Main Methods:

  • Literature review of studies investigating KRAS, PIK3CA, and PTEN in relation to anti-EGFR therapy in CRC.
  • Analysis of discrepant results regarding PIK3CA mutations and resistance.
  • Discussion of the clinical utility and challenges of PTEN assessment.

Main Results:

  • Wild-type KRAS is a prerequisite for anti-EGFR mAb sensitivity but does not guarantee it.
  • PIK3CA mutations have been investigated for their effect on resistance, with conflicting findings.
  • PTEN loss in metastases shows potential as a resistance predictor, but its clinical application is limited.

Conclusions:

  • Further research is needed to identify reliable biomarkers for predicting anti-EGFR therapy response in KRAS wild-type CRC patients.
  • PIK3CA and PTEN warrant further investigation as potential resistance markers.
  • Targeted therapies modulating the PI3K/AKT/mTOR pathway represent a promising but early-stage therapeutic avenue for CRC.

More Related Videos

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells10:13

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells

Published on: July 3, 2013

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...